Silence Therapeutics plc(SLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,877 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
SLN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Silence Therapeutics plc (SLN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SLN at 13.1/100 on a 32-signal composite quality model, placing it at rank #2,877 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Silence Therapeutics plc reports net income of $-12.3M, free cash flow of $1.5M. Top institutional holders of SLN by reported 13-F value include Siren, L.L.C., TCG Crossover Management, Redmile Group, based on the most recent SEC filings. SLN trades on the Nasdaq exchange and files with the SEC under CIK 1479615. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silence Therapeutics plc directly from SEC EDGAR. Silence Therapeutics plc's 13F Pro composite quality score has ranged between 6 and 29 since 2026, currently 13.1 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-12.3M
Free Cash Flow
Q2 2026
$1.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-98.7% YoYNet Income
-95.6% YoYOperating Income
-43.8% YoYEPS (Diluted)
-90.9% YoYTotal Assets
-35.1% YoYOp. Cash Flow
+7.9% YoYFree Cash Flow
+8.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $559.0K -98.7% | $43.3M +36.7% | $31.6M +46.1% | $21.7M | — | $5.3M |
| Net Income | $-88.6M -95.6% | $-45.3M +16.4% | $-54.2M -7.7% | $-50.3M | — | — |
| Operating Income | $-91.1M -43.8% | $-63.3M +1.7% | $-64.4M -5.5% | $-61.0M | — | — |
| EPS (Diluted) | $-0.63 -90.9% | $-0.33 +32.7% | $-0.49 +5.8% | $-0.52 | — | — |
| Total Assets | $131.4M -35.1% | $202.6M +69.6% | $119.4M | — | — | — |
| Operating Cash Flow | $-62.3M +7.9% | $-67.6M -36.8% | $-49.5M +13.3% | $-57.0M | — | — |
| Free Cash Flow | $-62.3M +8.1% | $-67.9M -37.0% | $-49.5M +13.5% | $-57.2M | — | — |
Get alerted when SLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Silence Therapeutics plc including:
Top Institutional Holders of SLN
Siren, L.L.C.
$36.4M3,311,438 shTCG Crossover Management, LLC
$33.3M3,033,560 shRedmile Group, LLC
$23.8M2,164,777 shNantahala Capital Management, LLC
$14.8M1,346,731 shCITADEL ADVISORS LLC
$14.6M1,329,625 shNextech Invest, Ltd.
$10.5M952,400 shMILLENNIUM MANAGEMENT LLC
$10.0M909,279 shTFG Asset Management GP Ltd
$8.4M764,256 shSoleus Capital Management, L.P.
$6.9M630,000 shBALYASNY ASSET MANAGEMENT L.P.
$6.7M610,980 sh
| Fund | Value | Shares |
|---|---|---|
| Siren, L.L.C. | $36.4M | 3,311,438 |
| TCG Crossover Management, LLC | $33.3M | 3,033,560 |
| Redmile Group, LLC | $23.8M | 2,164,777 |
| Nantahala Capital Management, LLC | $14.8M | 1,346,731 |
| CITADEL ADVISORS LLC | $14.6M | 1,329,625 |
| Nextech Invest, Ltd. | $10.5M | 952,400 |
| MILLENNIUM MANAGEMENT LLC | $10.0M | 909,279 |
| TFG Asset Management GP Ltd | $8.4M | 764,256 |
| Soleus Capital Management, L.P. | $6.9M | 630,000 |
| BALYASNY ASSET MANAGEMENT L.P. | $6.7M | 610,980 |
Companies Similar to SLN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Entrada Therapeutics, Inc.
Monte Rosa Therapeutics, Inc.
Voyager Therapeutics, Inc.
Zymeworks Inc.
Celldex Therapeutics, Inc.
ALUMIS INC.
Alector, Inc.
Wave Life Sciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SLN on your watchlist
Track score changes the day Silence Therapeutics plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SLN a good stock to buy?
13F Pro's AI-powered analysis of Silence Therapeutics plc (SLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SLN are available on the SLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SLN is classified as a small company.
Which hedge funds own SLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Silence Therapeutics plc's investment landscape.